Codexis, Inc.

Greetings, and welcome to the Codex fourth quarter and full year 2021 earnings conference call. At this time, all participants are in a listen-only mode. A question and answer session will follow the formal presentation. If anyone should require operator assistance during the conference, please press star zero on your telephone keypad. As a reminder, this conference is being recorded. I would now like to turn the conference over to Brendan Strong from Argo Partners.

Please go ahead. Thank you, operator. With me today are John Nichols, Codexus's president and chief executive officer, and Ross Taylor, Codexus's chief financial officer. Earlier today, Codexus issued a press release detailing the company's results for the fourth quarter and full year ended 2021 and provided guidance for 2022. This press release, along with a slide presentation that we plan to reference during today's call, are available under the investor relations section of the company's website, During this call, management will be making a number of forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995, including, without limitation, our guidance for 2022 revenues, product revenues and gross margin on product revenues, prospects for our life sciences tools, food sector, and biotherapeutics products businesses, and our expectations regarding sales of one of our proprietary enzymes to Pfizer, for the manufacturer of their COVID-19 antiviral therapeutic Paxlovid. To the extent that statements made by management are not descriptions of historical facts regarding sexes, they are forward-looking statements reflecting beliefs and expectations of management as of the statement date, February 24th, 2022. You should not place undue reliance on the forward-looking statements because they involve known and unknown risks, uncertainties, and other factors that are, in some cases, beyond the company's control and could materially affect actual results. In particular, there is significant uncertainty about the duration and impact of the COVID-19 pandemic. This means that results could change at any time and the currently contemplated impact of the virus on the company's operations, financial statements, and outlook is the best estimate based on available information. For details about these risks, please see the quarterly news release that accompanies this call, as well as the company's SEC filings, including Cadexus's annual report on Form 10-K filed with the SEC on March 1st, 2021, and Cadexus's quarterly report on Form 10-Q filed with the SEC on November 5th, 2021, and Cadexus's other periodic reports filed with the SEC. Cadexus expressly disclaims any intent or obligation to update forward-looking statements, except as required by law. I'll now turn the call over to John.

Thank you, Brendan. Good afternoon, everyone. We are very pleased to report exceptional fiscal year 2021 results for Codexys and to discuss the exciting growth drivers that will continue to accelerate company momentum through 2022 and beyond. In particular, I am extremely proud that we delivered our eighth consecutive year-on-year revenue growth. In addition to more than doubling our annual product revenue, we also delivered our highest total revenue in recent history of $104.8 million. And as our sales mix continues shifting toward higher margin products, we delivered our highest ever annual product gross margin as well. In addition to these accelerating financial metrics, we also made great strategic strides across all of our target markets. We'll go over each of those business areas in more detail shortly, But I'm super proud to highlight now our record performance against core fundamental growth metrics in 2021. In our biotherapeutic segment, we now have two Cody-Volver discovered candidates that have advanced into the clinical development stage. And in performance enzymes, we commercialized a record eight new products in the year. including our largest ever annual product sale to Pfizer for their COVID antiviral pill, Paxlovid. 2022 is set to continue the company's acceleration following the record strong finish in 2021. Total company sales are set to grow 50% year on year again in 2022. Leading the way to deliver double digit sales growth, excluding the large Paxlovid enzyme business, is the high-growth life science tools market, which is set to deliver 50-plus percent revenue growth this year. In the biotherapeutic segment, we expect to have three developmental candidates, up from one currently, executing IND-enabling work toward the clinic by the end of 2022. Driven by an increasingly profitable performance enzymes business, and a robust year-end cash balance of $117 million. We are poised to continue to invest in the growing number of high ROI opportunities we are developing, positioning us to continue this growth well beyond 2022 as well. All core fundamental metrics show that we are delivering on the promise of translating the power of synthetic biology into tangible real-world benefits and impact. In our performance enzymes business, we are on track to deliver a nearly four-fold increase in product revenues in just two years. Our technology and products are benefiting a widening set of customer relationships in parallel, noting that our customers with significant size have expanded by 37 percent over the last two years. We manage dozens of developmental stage programs with these customers, but the fruits of both of our efforts come when the program fully commercializes, at which point both we and our customers enjoy the recurring benefits from the use of the products we engineer, patent, and scale. Hence, it is fabulous to see our pace of commercialization take off, nearly doubling over the past year and a half. Once one of our products gets commercially specified into our customer's process, given our strong intellectual property position, we are poised to serve the customer with that product for many years, if not decades to come. And finally, notice the step-out progress we are making in our novel biotherapeutic segment, where we expect to have five therapeutic candidates in either clinical or IND-enabling stages by the end of 2022. This is up from just one in 2019. Whether de-risked through partnership or wholly owned, these are by far the largest potential products our technology can aspire to create. Discovering lead drug candidates leverages our core Cote d'Ivoire platform. Driving those patented candidates towards the clinic leverages our decades-long experience in enzyme process development and manufacturing. Validation of those drug candidates in the clinic is where the real value creation happens. It's incredibly gratifying to see us step up the advancement of the biotherapeutic pipeline and its value creation over these recent years, and we look forward to maintaining this exciting momentum. Now let me shift to more detailed reviews of our target markets, first starting with sustainable manufacturing. This is where Codexys has differentiated itself as the global leader in overhauling processes utilizing engineered enzymes. We serve a growing diverse group of branded and generic drug companies, food and beverage companies, and industrial manufacturers. Thanks to the scale and constantly accelerating speed of our unique CodeEvolver platform, Codexis has an unparalleled ability to discover and commercialize high-value enzymes for a growing array of applications. Our novel, high-performance enzymes reliably enable our customers to dramatically reduce the cost and increase the sustainability of manufacturing their end products. Compared to using traditional non-enzymatic chemistry, which is capital-intensive and inefficient, our engineered enzymes decrease capital needs meaningfully while also enabling higher yields, reduced energy usage, and lower waste generation. Small molecule pharmaceutical processes have been and continue to be a core target for growing the sustainable manufacturing market for Codexys. Here, our business is accelerating substantially, with product sales growing at a 36% compound annual growth rate over the last five years. Our reputation and competitive advantages are well known, with us doing at least some amount of business with 21 of the top 25 largest pharmaceutical companies in the world, helping them adopt and install novel Cadexus enzymes for manufacturing their APIs. These are large household names that are increasingly putting great trust in us, depending on our products to manufacture medicines that improve the lives of people around the world. Eleven pharmaceutical customers now each generate in excess of $1 million revenue for us, up nicely from eight last year. In 2021, we secured the largest product sale in company history for a proprietary Codexis enzyme to manufacture Paxlovid, Pfizer's COVID-19 antiviral pill. which has been granted emergency use authorization by the FDA, as well as corresponding international marketing approvals. This success represents a historic milestone for Cadexis, demonstrating the agility and speed of our commercial supply chain and manufacturing capabilities to generate unprecedented enzyme quantities in support of Pfizer making Paxlovid available to COVID-19 patients as quickly and widely as possible. Following last year's record sales of $34.5 million for Paxlovid, we are set up to more than double our supply in 2022 to between $75 and $80 million. Orders are now in hand to cover that demand in 2022, and we have also secured purchase orders for deliveries in early 2023 that give us visibility into at least the majority of this revenue stream continuing into next year as well. Prompted by this strengthened and extended demand from Pfizer, we have gotten our two leading custom manufacturing partners to expand their capacities and have secured additional new production from two other high-quality CMO partners. Not only will that help us continue to stay ahead of Pfizer's enzyme requirements, but this will also bring longer-term supply chain robustness to us as we continue to grow our overall enzyme production needs. The Cadexis team has done an amazing job capitalizing on this opportunity of unprecedented scale. We are honored to have earned Pfizer's trust and confidence to be a key partner in the manufacturing process of such a critical drug, and we look forward to continuing to support Pfizer's manufacturing of this essential treatment for COVID-19 patients. In addition to our work with branded drug manufacturers, the cost savings provided by our high performance enzymes have positioned Codexys to be a key partner to stakeholders throughout the life cycle of a drug, including when the drug goes off patent. In 2021, we have begun to demonstrate through the announcement of our first two deals that we will sustain ongoing business from both the branded and generic versions of CIDIC Lipton as that API ultimately becomes available in generic form. We have refined our CodeEvolver platform and business model approaches with the pharmaceutical industry over two decades now, and that has been leveraged to extend us successfully into exciting new, much larger addressable verticals like food and industrials over the last few years. These applications have shorter developmental timelines and lower regulatory hurdles than pharma manufacturing, allowing us to commercialize enzymes more quickly as well. 2021 was an excellent year of growth for us in the food sector. Enzymes used in the manufacture of Tate & Lyle's Dulcia Prima Allulose and Tastevia Sweeteners delivered seven-digit year-on-year product sales growth. Combined with our newly commercialized enzyme for CalSec's new light stable hop products, our sales to these two key customers more than doubled to exceed $3 million in 2021. We are encouraged that both of these key partners expect that they will continue to increase their customer adoption and penetration downstream, boding well for our growth in 2022 and beyond. As their sales grow, our sales grow. Beyond these commercial food applications, we made early inroads into a range of other developmental food and industrial targets, and we look forward to converting some of these exciting opportunities into new and innovative commercial sources of product revenues over time. Stay tuned for that. Switching to the life science tools, this market continues to be a very high growth area for Codexys. From our initial market entry just three years ago, we generated over $7 million of sales in this market in 2021, doubled from the prior year. We expect another 50% growth in 2022, targeting over $12 million in revenue this year. Our engineered enzymes enable improvements in next-generation sequencing and molecular diagnostics, DNA and RNA synthesis, and more. The market is very attractive given its rapid commercialization cycles and above average margin prospects. This market also affords us the opportunity to develop products that can be marketed to multiple customers. 2021 was a groundbreaking year in this regard, with the team successfully commercializing and launching three new products into the sector. Early in 2021, we launched Codex HiFi DNA polymerase, for use in next generation sequencing. Based on our comparison against commercially leading DNA polymerases, HiFi generated significantly higher NGS diagnostic fidelity. Around that same time, we launched our Codex HiCap RNA polymerase for use in messenger RNA manufacturing. Our tests demonstrated that HiCap drove down the need for cap agent as well as reduce the production of undesirable double-stranded RNA byproduct compared with commercially available RNA polymerases. With a growing list of customer trial successes in 2021, customers increasingly agreed. Our first commercial sales followed, and meaningful sales in a range of $1 million for each of these unique new products are expected in 2022. In December, we launched our third Life Science Tools product, Codex High Temp Reverse Transcriptase, for use in one-step quantitative reverse transcription, currently used widely for viral diagnostic testing. This enzyme is specifically engineered and optimized for enhanced thermal stability and robustness to address well-known challenges in handling clinical samples. Given the recent unprecedented demand for PCR testing due to the COVID-19 pandemic, this Codexis enzyme is a timely addition to our portfolio amidst supply chain and sample processing workflow challenges. And the product is currently available to customers in bulk supply quantities. In addition to these three commercial product launches, we are making exciting advancements in our groundbreaking partnership with Molecular Assemblies. Here, Codexis is leveraging the power of Codevolver to deliver dramatic performance improvements over the current chemical process for DNA synthesis by engineering enzymes designed to make MAIs process a commercially viable, cost-effective, and differentiated solution to manufacturing quality long-chain DNA. In parallel, Molecular Assemblies has been scaling their manufacturing platform and building a go-to-market team to enable their business commercialization in 2023. Our DNA synthesis enzyme has recently been finalized after one of the most intense and extended enzyme engineering campaigns in our company history. Underscoring our confidence in our enzyme's competitive advantage and the work that Molecular Assemblies is performing, we stepped up our investment in 2021 to become their second largest shareholder. Finally, we continue to experience strong demand for a range of partnered enzyme engineering programs for those life science applications where a bespoke engineered enzyme product can unlock value. Driving near-term R&D revenue generation, these programs add low-risk sources of potential future commercializations as well. No other market area for the company is surfacing an abundance of opportunities comparable to those within life sciences. Enzymes are core to unlocking unique value across the life science space, and Cody Barber's ability to design in unique performance attributes is proving to be a widely applicable value creating tool. Between penetration growth for our recently launched products, new product launches with broad customer applicability, and new high-synergy inorganic investment approaches, look for this sector to continue to be an important source of top-line growth for the company for the foreseeable future. Shifting to the biotherapeutic segment, we are thrilled with our progress building and advancing a high-value pipeline of oral biologics and gene therapy candidates. Five-plus years in, Now with over a dozen programs in our pipeline, there is no question to us that our CodeEvolver platform is validated as a unique discovery engine, creating differentiated large molecule drug candidates. The majority of our programs are supported by growing partnerships with Nestle Health Science and Takeda. But our strategy to increasingly invest to keep more of our drug discoveries value accruing to us is starting to generate momentum. Of the five most advanced assets in our pipeline, two are wholly owned and two are owned 50% by Codexis. Recalling that each of these product targets have by far the highest peak revenue potential for the company, but also noting their relatively higher risks, we believe we are striking a very attractive and compelling strategic balance for the segment's return on our growing investments. 2021 was a breakout year for building out our growing biotherapeutics pipeline. We segment the pipeline between our two unique value propositions. First, that Cody Ballard can enable us to discover large molecule drugs that can be safe, efficacious, and stable in the human GI tract so that they can be taken in a convenient, orally delivered form. This approach makes up the majority of our pipeline, but also all of our most advanced assets. Second, that co-devolver can enable the discovery of safer, more efficacious gene therapy constructs by focusing on engineering unique performance enhancements of the transgene that is packaged and delivered by the gene therapy vector. This is a newer value-creating approach within our pipeline, but it is bearing terrific early development success. Starting with our oral biologics pipeline assets, our most advanced program is CDX6114 for PKU, which is in phase one clinical trials and fully outlicensed to Nestle Health Science. Here, Nestle has informed that progress to initiate the next clinical trial, a solid-dose multiple ascending dose study at multiple sites and patients has been slowed due to COVID-related issues. The program continues to be fully supported by Nestle, and the trial results are now expected in 2023. Last quarter, we were thrilled to announce that a second Cody-Bauber discovered biotherapeutic candidate reached the clinical stage with the initiation of a phase one study for CDX7108 for the treatment of exocrine pancreatic insufficiency. EPI is a debilitating condition of the GI tract that is caused by conditions that impair pancreatic function, like pancreatitis, pancreatic cancer, and Crohn's disease. The current standard of care for this condition, pancreatic enzyme replacement therapies, or PERTs, are limited in efficacy due to the GI instability of their lipase components. CDX7108 an orally administered GI-active lipase was precisely engineered to overcome this limitation of traditional PERPs, as it is highly stable to the acidic conditions in the stomach. The CDX7108, which is 50-50 owned and partnered with Nestle Health Science, is expected to read out the phase one trial results late in 2022. Just recently, we also announced that the FDA granted orphan drug designation and rare pediatric disease designation to CDX6512, our wholly owned candidate for the treatment of homocysteine urea, a rare inborn error of amino acid metabolism disorder estimated to affect one in 150,000 people worldwide. At the 14th International Congress of Inborn Errors of Metabolism in November, we presented preclinical data highlighting the exciting potential for CDX6512 to become a first-in-class oral enzyme therapeutic for a condition with limited treatment options to date. We are currently lining up and advancing IMD enabling work for CDX6512 to enable the initiation of clinical trials by the end of 2023 or early 2024. At the same IEM conference late last year, We also presented exciting preclinical data for CDX6210, our wholly owned candidate for the treatment of maple syrup urine disease or MSUD. We expect that CDX6210 will begin IMD enabling work later in 2022. Shifting to the gene therapy programs within our pipeline, we are very encouraged by the progress we're making within our four program partnership with Takeda. In 2021, Takeda exercised their unilateral option to add a fourth program targeting another lysosomal storage disorder to the partnership, a clear indication of their enthusiasm for Cody-Volver's ability to improve gene therapy constructs. In addition, for all three of the initial programs targeting Fabry and Pompe diseases plus an undisclosed blood factor disorder, we have finalized the discovery work and have transferred our Codevolver-improved lead transgenes. CACADA is inserting those into their proprietary vectors and is advancing preclinical validation of these gene therapy candidates. In parallel, Codexys has successfully established an infrastructure to do its own preclinical gene therapy research, and we have already made exciting discovery progress there, targeting another rare disease. It's highly rewarding to see all the progress the team is making in the biotherapeutic segment, and we look forward to sharing our continued progress here with you. Let me now hand over the call to Ross to take you through our financial results in more detail.

Thanks, John, and good afternoon, everyone. We delivered incredibly strong results in 2021. Starting with the fourth quarter, total revenues were $24.5 million, up 16% compared to the prior year period. On a segment basis, $22.1 million was from the performance enzyme segment, and $2.4 million was from novel biotherapeutics. This compares with $16.7 million and $4.3 million for the performance enzymes and novel biotherapeutics segments, respectively, for the prior year period. Product revenue for the fourth quarter of 2021 was $17.0 million, up 39% compared to $12.2 million for the prior year period. Product revenues from the sales of enzyme to Pfizer for Paxlovid were $11.3 million in the fourth quarter. Gross margin on product revenue for the fourth quarter of 2021 was 60.0% compared with 52.0% in the fourth quarter of 2020. The increase was due to favorable product mix. Notably, the improvement from mix was partially offset by a reclassification of freight expenses related to product sales from SG&A expense into cost of goods sold during Q4. Excluding this, our product gross profit margin would have been about 70% in Q4. Turning to operating expenses, our R&D expenses for the fourth quarter of 2021 were $16.4 million, up from $10.4 million in the prior year period. In addition, SG&A expenses for the fourth quarter of 2021 were $11.7 million, up from $8.7 million for the prior year period. The net loss for the fourth quarter of 2021 was $10.2 million, or 16 cents per share, compared with a net loss of $3.9 million, or 6 cents per share, for the fourth quarter of 2020. Turning to the full year results, total revenues for fiscal 2021 were $104.8 million, up 52% from 2020. This is the highest annual growth that we have delivered in more than 10 years. On a segment basis, $90.5 million in revenue was from the performance enzyme segment, and $14.2 million was from novel biotherapeutics. This compares to $48.1 million and $21.0 million, respectively, in 2020. Revenue growth in our performance enzymes business was primarily driven by Pfizer, with sales of the enzyme used to manufacture Paxlovid equaling $34.5 million in fiscal 2021. In 2020, product sales to Pfizer related to Paxlovid represented less than $100,000 in revenue. Revenue in our novel biotherapeutic business is entirely driven by the revenue that we generate for R&D services, milestones, and upfront payments. As you may recall, R&D revenue in our biotherapeutics business was strong in 2020 and benefited from upfront licensing revenue from Takeda, creating a difficult comparison for us in 2021. Product revenues for fiscal 2021 were $70.7 million, up 134% from 2020. Most of the increase in our product revenue was driven by Paxlovid. It is important to note, however, that if we exclude sales that to Pfizer related to Paxlovid, our product revenue grew 20% from 2020. This is an exceptional result given the intense focus of our entire organization during the year on delivering on the large revenue opportunity presented by Pfizer. Gross margin on product revenue for the fiscal year 2021 was 68.6%, up from 54.5% in 2020 due to favorable product mix As John indicated, this was our highest ever annual product gross margin. Turning to expenses, we made investments throughout 2021 to expand our research and development capabilities and to expand our SG&A infrastructure. We will continue to do this in 2022, particularly in R&D. R&D expenses for fiscal year 2021 were $55.9 million, up from $44.2 million in fiscal 2020, The R&D increases were primarily due to increased headcount and higher expenses for stock compensation, lab supplies, outside services, and depreciation. SG&A expenses for fiscal year 2021 were $49.3 million compared to $35.0 million in fiscal 2020. The increase in SG&A expenses was primarily due to higher expenses for payroll and stock compensation as well as higher legal fees and higher expenses for recruiting and consultants. The net loss for fiscal year 2021 was $21.2 million, or 33 cents per share, compared to $24.0 million, or 40 cents per share, in fiscal 2020. Turning to the balance sheet, cash and cash equivalents as of December 31, 2021, were $116.8 million, which puts us in a strong position as we look to seize the company's growth opportunities. I will also note that to date we have not drawn any funds from our $50 million ATM facility that we put in place in May of 2021. Let's spend a minute talking about our financial results by segment. As you can see, we have a highly profitable and growing performance enzymes business with segment level operating margins of 37% in 2021. This was nearly enough operating income to support all of our corporate overhead expense in 2021. As you might expect, our novel biotherapeutic business generated an operating loss in 2021, as is typical for almost any pre-commercial stage biotech company. Our novel biotherapeutic segment reported revenues of $14 million and an operating loss of $19 million before corporate overhead expense. We plan to continue to thoughtfully invest in our biotherapeutic segment in order to grow the value of the assets in our pipeline. Turning to guidance, we expect total revenues in 2022 to be between 152 and $158 million, which represents growth of 45% to 51% over 2021. Importantly, we expect this will be driven by growth for many customers, not just Pfizer. If we exclude Pfizer from both 2022 and 2021, we anticipate revenue growth of 10% or more in 2022. We expect approximately 45% of 2022 revenue to be reported in the first half of the year and 55% in the second half of the year. Within the first half, we expect about 40% of the first half's revenues will be in Q1 and the remainder in Q2. We expect the growth in total revenues for the year to be primarily driven by our performance enzyme segments. with some revenue growth in our biotherapeutic segments as well. We expect product sales to be in the range of 112 million to $118 million in 2022, including 75 million to $80 million related to Pfizer's Paxlovid. We expect gross margin on product sales to be between 65% and 70%. As we continue to invest in the business, we anticipate growing the combined expenses for R&D and SG&A to approximately $150 million in 2022. The substantial majority of the increase will be due to higher levels of R&D spending, including I&D enabling work for several programs in our novel biotherapeutics business, ongoing expense related to our phase one clinical trials for CDX 7108, expansion of the number of R&D teams to 25 plus, and expenses associated with our new facility in San Carlos that we expanded into and occupied in December. Year-over-year growth in our investments in R&D and SG&A is being funded by our growing revenue base and will enable our revenue growth in the years ahead. For modeling purposes, you should anticipate that combined expenses for R&D and SG&A will be approximately 10% higher in the second half of 2022 relative to the first half of the year. In summary, we had an outstanding fiscal 2021, and we are confident about our future growth prospects. With that, I'll turn the call back to John.

Great update, Ross, and nice to see the financials in such terrific shape as we gear up for another year of step-out top-line growth in 2022. Opportunities abound for Cadex to tap into our differentiated, constantly improving platform to create value in our target markets. In this environment, we will strategically continue to keep our foot on the gas to maximize the company's medium and longer term growth. It all starts with our capacity to discover new patentable value creating products. And in 2022, We are continuing the work we started last year to add to our R&D capacity. Enzyme discoveries are the lifeblood of Cadexis, and we are showcasing our ability to translate those into a growing cascade of commercializing products. With added platform capacity, that flywheel will continue to accelerate for our future. Leveraging the growing profits from our accelerating top line, and our solid balance sheet, we are also strategically tapping into a range of medium-term accelerators as well. Investments to keep our platform constantly improving and widening our competitive advantage. Self-funding a healthy minority of our projects so we can extract more long-term value from our successful innovations. Steadily increasing the percent of opportunities like for life science tools, food, and industrial markets, where peak revenues are projected larger and products can commercialize quicker. Investing in IND enabling and early clinical development to deliver higher value from our differentiated biotherapeutic discoveries. And synergistically investing in companies whose businesses complement ours and who can benefit from accessing our platform technology. Each of these leverage our core, enhancing high return growth and brightening our future. All of this sets us up to deliver another strong year of successes and growth in 2022. We have clear visibility to the multiple catalysts that will accelerate the company's growth ambitions across all of our target markets. From executing another record year serving Pfizer, to another year of exceptional revenue growth in life science tools, to more new product developments and launches, to preclinical and clinical advancements across our biotherapeutics pipeline. We're excited to deliver against all of these and more in 2022. Now we'd be happy to answer your questions. Operator?

At this time, we'll be conducting a question and answer session. If you would like to ask a question, please press star one on your telephone keypad. A confirmation tone will indicate that your line is in the question queue. You may press star two if you would like to remove your question from the queue. For participants using speaker equipment, it may be necessary to pick up your handset before pressing the start key. One moment, please, while we poll for questions. Our first question comes from Brandon Couliard with Jefferies. Please proceed with your question.

Hey, thanks. Good afternoon. John, a couple things on the guide. So if my math is right, for product revs, if I strip out Pfizer in both years, it would suggest only a couple million dollars of base product growth. Is that right? And what are some of the kind of moving parts there to think about? And then in terms of the Pfizer-Paxlovid, can you just sort of Give us a feel for, you know, your level of visibility to 22 revenues there. And would it be logical to expect additional POs to come in over the balance of the year that would contribute to REVs later this year that's not embedded in guidance perhaps?

Yeah. Hey, thanks, Brandon. Really good questions. So I'll take those in turn. So the first question you have is about product revenues outside of the Pfizer-Paxlovid enzyme sales. And here, your math is correct. We are showing some modest growth in product revenues in 2022's guidance outlook versus 2021. And I think, you know, anyone who's been following Codexys like you for years sees that there are a number of puts and takes every year in terms of product sales that ultimately over time lead to fairly explosive years' growth. You can see that our product sales have compounded 36% per year over the last five years. Some of that, of course, is from the successful business with Pfizer last year, but most of that growth is coming from the commercialization of new products that have been in the developmental stage and the growth of those products as they finally reach market. And so for us, you know, just a few million growth year over year in product sales in 2022, probably maybe a little bit on the conservative side, but also it's just, you know, we are fully confident in our ability to continue to translate developmental stage products into recurring commercial stage products that are going to ensure that fundamentally we're going to continue to lift up our product sales in the performance enzyme side significantly, like we have consistently over these past years. The second question was in regards to Paxlovid enzyme sales themselves. In my prepared remarks, you heard that we actually have orders in hand right now that cover the guidance range that Ross detailed of $75 to $80 million of enzyme sales this year. It's unlikely that we're going to see material new enzyme POs from Pfizer that are going to affect that number. I think we're fairly confident in that range and unlikely to see much more, although it's possible. We also shared that we already have purchase orders in hand that that carry us into early 2023 that make up at least the majority of the guidance range that we have for 2022, already for 2023. So that's giving us visibility with POs in the hand all the way well into 2023. So pretty solid, actually more solid visibility in this product than we're historically used to with Pfizer.

Okay, that's very helpful. And then second question on the biotherapeutics side. That pipeline has grown considerably. Those programs are advancing further in development. That's reflected in the OPEX spend for next year. What's the likelihood that one or more of those get partnered out at some point this year? And Ross, could you just put a pin in your expected cash burn for 22, what that would kind of shake out to at the bottom line?

Yeah, I'll take the first question, and, Ross, you can handle the second question. You know, our plan for the three IND-enabling stage programs, two of them are wholly owned. This is the two products that we reported scientific data at this inborn era of metabolism conference in November. We plan to take those forward on our own for the foreseeable future, so I would not see Codex is partnering CDX6512 for homocystinuria, nor CDX6210 for maple syrup urine disease. Not in that timeframe. Yeah, I think we're really encouraged by the data. We're fully funding the preclinical development expenses to reach early clinical stage. And we had announced in the prepared remarks that for homocystinuria, that's gonna be around the end of next year. and maple syrup urine disease a little bit later. So I think we're going to strategically fund those. The preclinical data was very compelling, and we're going to look to get some early data as our strategy in clinical trials and early clinical trials for those two compounds. The third program that we expect to start IND-enabling stage preclinical development this year is one of the 50-50 partnered programs with Nestle Health Science. It's actually the third program that we started to work on with them. Of course, the first one being PKU, the second one being CDX7108, which just started clinical trials. The third one, we've yet to detail that yet, but that program's done very, very well, and we expect to start IND enabling work in that area. So that one's already 50-50 partnered with Nestle.

Let's see, the last part of your question, Brandon, related to cash burn, we burned about $32 million in 2021, and our estimates right now are that we'll probably burn a similar amount to that in 2022, so probably right around $30, $32 million in 2022. Helpful. Thank you. Thanks, Brian.

Our next question comes from Matt Hewitt with Craig Hellam Capital Group. Please proceed with your question.

Good afternoon and congratulations on all the progress last year and thank you for providing all the details as it pertains to the 22 guidance. Maybe first up for me, just a point of clarification regarding Paxlovid. Pfizer has partnered or licensed that out to a few other manufacturers. Are you providing enzymes to those parties as well, and is that part of the Pfizer contract that you have, or do you have the opportunity to sign additional contracts with those third parties, and what kind of contribution can we anticipate from those?

Yeah, so any business through the medicines patent pool with generic companies is not part of our Pfizer relationship. Our Pfizer relationship is for directly for Pfizer's developed world business. The possibility to supply additional enzyme to those generic companies is certainly there. We don't have a lot of visibility yet. It's lagging significantly behind the manufacturing scale-up that we're participating with Pfizer. So, we don't see it as a big contributor in 2022. if at all, and we'll have to keep you and our investors updated as we move through this year as that opportunity unfolds and gives us some visibility into what that might look like for as we move through 2022 and into 2023.

Got it. That's helpful. And then maybe just a follow-up regarding the commercialization efforts or progress with those two internally owned programs. It sounds like you're planning to take those through the IND stage into phase one. Is there a point at which you would look to partner those out, or at this point in time, are you thinking that you might take those all the way through to commercialization should they get to that stage?

Yeah, hey, great question, and I'm glad you asked it just to clarify. I mean, Conexus is really not set up in the foreseeable future to bring drugs directly to market to patients. That's not who we are. However, we are looking to validate our discoveries to inflect higher value by advancing those candidates through preclinical validation and through early clinical validation. You know, but once we get early clinical validation and we start moving into the time-consumably costly later stage clinical trials, excuse me, we're almost certain to look for partners to bear those operational needs and to ultimately bring those to market. So I think, you know, we're set up to bring our biotherapeutic assets farther maybe than we have historically, but not too far, at least the way we're set up as a company today to just really, you know, invest to bring higher value to those assets. But ultimately, we're going to be looking for partners to capitalize the very heavy lift of larger clinical trials and bringing products to market.

That makes complete sense. So thank you for the clarification on that. Maybe one last one, then I'll hop back into the queue. Regarding the product gross margins, obviously there's a mixed component that you talked about in Q4. You provided some guidance for 22 products. As you look, and maybe without getting into specific products, but as you look at the programs that you're working on, the enzymes that you're providing, are life science tools maybe higher margin? Are drug-based enzymes, are either one a higher margin and can move the needle in one quarter or the other? Or are they pretty similar regardless of the end customer and use?

Yeah, I don't see a lot of differentiation anymore. A couple years back, the life science tools target margins were higher, but we've been very successful to lift up our average gross margin to pharmaceutical manufacturing applications and customers over the recent years. So they're fairly close. I mean, a given product could be significantly higher margin than another product, but as a grouping, I think both the life science tools, the food and industrial sectors, and the pharma manufacturing are all fairly similar in new product margins in this range of the guide range that Ross detailed for us.

Got it. Thank you very much. Thanks, Matt.

Our next question comes from Jacob Johnson with Stevens. Please proceed with your question.

Hey, good afternoon, guys. John, maybe first question just on kind of capital allocation investments in the business. You're taking this kind of bolus of revenues from Pfizer, and it seems kind of reinvesting it back in the business. I guess longer term, you've got this very profitable performance enzyme business now. You're investing in novel biotherapeutics more. Can you just talk about the philosophy that as we see the top line grows, your desire to reinvest that back into the business kind of longer term beyond this year?

Yeah, yeah. Really good question, Jacob. Thanks. You know, first and foremost, we're investing in the capacity to discover and develop enzymes. And we stepped that up last year, and we continue to step up a little bit more moderated in 2022 versus 2021, but we see continued demand for enzyme engineering, and that applies across the company's target markets and sectors. And that's a big part of the lift. Now, beyond that, the expenses to move biotherapeutic discoveries through preclinical development, you know, per asset is pretty significant. And so you see Ross detailed it, you know, that we're going to spend more because we're moving from a typical year where we had one biotherapeutic program in the preclinical development chapter to this year we're going to be having three. And so three in parallel. So that's going to be a significant investment to move more candidates more quickly into the clinic in the biotherapeutics area. And so hopefully we can continue to see great preclinical data that warrants us making those kinds of investments going forward in the future. We don't have that kind of expense profile for commercializing or developing a performance enzyme in the performance enzyme segment. So I'd say that we're strategically fully funding the advancement of the biotherapeutics pipeline at this stage. We're very excited by the data and the prospects there. And we continue to build out the company's R&D capacity to really expand the flywheel of new product discovery, which ultimately will translate into more and more commercial products for our future. And, you know, on that point, it's really amazing and terrific to see how many of our products that were in development are now moving into the commercial stage, eight in the last year, you know, almost double over the last two years. That's really the proof. That's the proof point. We do all this discovery. We share our pipeline snapshot every year. We show that we have many dozens of programs. And really the fruit is to bring them to the commercial stage. So the cost to bring them to that stage is far less significant in the performance enzyme side. So I think over time, you'll see the cost growth taper materially in enzymes versus biotherapeutics, but we're gonna be smart about the spending in biotherapeutics as well.

Got it, that's a super helpful context. Thanks for that, John. And then maybe just as a follow-up, just, you know, it's been a while since you did a CodeEvolver license, you know, a lot of focus and talk about kind of the self-funded work you're doing. Can you just, maybe your latest thoughts on, you know, the pipeline or potential for additional CodeEvolver licenses down the road?

Yeah, yeah, still a great strategy. It's paid great dividends for the company to move large pharmaceutical companies from doing one project at a time to ultimately endorsing a major investment in a Cody Barber platform license. And we've done three of those, as you well know, with GSK, Merck, and Novartis. We finished the Novartis tech transfer last year. And we continue to advance, widen our adoption strategy, and penetration in essentially all of the large pharmaceutical companies. And so over time, we see a continued prospect for other large pharmaceutical companies to move into a state of having the return on investment to buy the Cody Barber platform license. We didn't build any expectation of of doing a Cote d'Ivoire deal in 2022 into our guidance outlook. It's not likely that we will initiate a fourth Cote d'Ivoire license this year. It's possible, but it's not likely. But we continue to support this strategy because it's a great validation of our technology, and economically, we think it's far more attractive than working one project at a time with these kinds of customers.

Got it. Thanks for taking the questions.

Thanks, Jacob.

As a reminder, if you would like to ask a question, please press star one on your telephone keypad. Our next question comes from Swayam Pakula Ramakant with HC Wainwright. Please proceed with your question.

Thank you. This is RK from HC Wainwright. Good afternoon, John and Ross. Thinking about seragliptin and the generic um that are um that you have um signed some agreements with you know any um expectations uh from from that uh in um in 22 and beyond um i know it it probably dwarfs against a pfizer but uh just trying to understand where things are there yeah thanks rk um you know we're really

very much on track with our plans and expectations to continue to have a significant enzyme business for sitagliptin even after sitagliptin moves into the generic chapter. The timing of generic is very uncertain. There's a lot of legal discussions about when is loss of exclusivity for in various countries in the world. But in 2021, we showcased two deals. First and foremost was a continuation of our business with Merck. And, of course, Merck, even as the drug is generic, will continue to have a double-digit market share, we expect, in the manufacture of citagliptin active, and that deal shows that we'll still be the enzyme of choice for their manufacture. And then we showcased a second deal, and this is with a major Indian generic company in a unique partnership that showcases we're going to, you know, have positions with generic companies as well. And recall, our patents for our enzyme, which liberated tremendous cost savings for Merck when it was installed almost 10 years ago, those patents extend well beyond Merck's loss of exclusivity. So this company, Almelo, saw the value-creating possibilities of using our enzyme, as have many other generic companies. So it's been a very active area. These are the first two deals. We expect more, so hang on, and we'll update you on getting more of these deals in place. And then as time goes by, we'll see this generic market unfold. We'll see our sales to Merck go down but continue, and we'll see our sales to other generic companies start to make up that difference, we hope and believe.

Thank you for that. And then on the life science tools business, certainly the growth has been pretty good, and you're expecting another 50% growth over the next year. In terms of the DNA synthesis enzyme launch that you're talking about for 22, what commentary would you give on expectations, launch timings, and how we should think about, you know, the trajectory of that product or that, yeah, that product in the market.

Yeah. Hey, thanks. So the DNA synthesis enzyme project has been really exciting for Cadexis. And you've seen us showcase our partnership with molecular assemblies over the last year and a half. So in today's prepared remarks, I highlighted that we are finished now with the enzyme engineering. We have We have radically overhauled the enzyme that's needed to do enzymatic DNA synthesis using our CodeEvolver platform now for 18 months, a very, very intensive program. It needed to be that intensive because the performance improvements, the yield, the activity, the thermal stability that we needed to impart on that enzyme were enormous, and we have accomplished it. So we finished the enzyme engineering. We are in the middle of discussing with molecular assemblies the commercialization of that enzyme, so stay tuned for that. And then really most of the work shifts over to molecular assemblies. And as I shared also in the prepared remarks, we have seen molecular assemblies build up their manufacturing platforms significantly over the last year especially, and they continue to invest in that. They're building a go-to-market team so that they can start to set up to be able to sell DNA synthesis, synthesized DNA in competition with a growing market who's already serving that, a growing set of suppliers who are already serving that market. Their commercialization is an important milestone thereafter. When are they out in the market selling custom genes and DNA? We hear from them and we serve on their board and we're the second largest investor in that company that that is set up for 2023. So you'll see announcements of us firming the enzyme part of the collaboration. We'll start to supply enzyme to molecular assemblies, but small quantities in 2022. And then molecular assemblies will start to line up for their commercialization and ultimately start selling into the DNA synthesis market in 2023. And that's when the consumption of the enzyme will kick into a much higher gear and hopefully they will successfully compete and our equity investments in molecular assemblies will start to pay off as well.

Fantastic. So one last question on biotherapeutics business. Obviously there you have a deep pipeline with almost a dozen or so. products in the pipeline right now, but do you think you are getting to the point of resource constraint or do you think you'll be adding more to that pipeline of molecules in either in discovery or preclinical stages?

I think you could see us adding some selectively into the discovery stage of our pipeline. But you're seeing Codexys start to mature the assets in the pipeline as the priority. The partners that we're working with, Takeda and Nessa Health Science, are helping to fund the advancement of the co-devolver Codexys discovered biotherapeutics are self-funded. We're starting to move those towards the clinic. So it's more about the advancement of the dozen or so pipeline assets than the expansion of those. But you could see us continue to bring in other programs at a discovery stage smartly to continue to validate the applicability and the widening applicability of our platform as a drug discovery engine.

Thank you. Thank you for taking all my questions.

Thank you, R.K.

Ladies and gentlemen, we have reached the end of the question and answer session, and I would now like to turn the call back over to John Nichols for closing remarks.

Thank you again, everyone, for joining us today. Today is officially two days from our 20th anniversary as a company this Saturday. Exciting milestone for Codexys, so thank you for joining us today. As a reminder, we will be attending the upcoming Cowan Healthcare Conference the week of March 7th. We look forward to continuing to update you on Codexus's progress. Thank you very much again.

This concludes today's conference. You may disconnect your lines at this time. Thank you for your participation.